Skip to content

US · MDLN · MEDICAL - INSTRUMENTS & SUPPLIES

Medline Inc. (MDLN) intrinsic value and stock valuation

$37.04as of 2026-11-21 · Mkt cap 31B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Medline Inc. DCF and intrinsic value

InvestorsCraft values MDLN with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from MDLN’s statements →

Medline Inc. Graham Number

Graham Number: $27.62d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Northfield, IL 60093 medline.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$28.4B
20222025
Net income
$1.16B
20222025
Free cash flow
$1.3B
20222025
Total equity
$19.3B
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$28.4B$25.5B$23.2B$21.4B
Operating income$2.21B$2.23B$1.44B$870M
Net income$1.16B$1.2B$234M-$-25M
EPSd$1.43M$1.52M$297.3K-$-31.76K
Operating cash flow$1.74B$1.77B$1.69B$187M
Capital expenditure-$-447M-$-364M-$-285M-$-254M
Free cash flow$1.3B$1.41B$1.4B-$-67M
Total assets$38.5B$36B$36.1B—
Total debt$12.6B$16.9B$16.8B—
Net debt$10.6B$16.6B$15.2B—
Total equity$19.3B$16.5B$17B—
Cash and short-term investments$1.94B$250M$1.59B—
Income statement
2025202420232022
Revenue$28.4B$25.5B$23.2B$21.4B
Cost of revenue$20.9B$19.2B$18B$16.9B
Gross profit$7.52B$6.29B$5.22B$4.56B
Research and development expenses$0.00$67M$60M$58M
Selling, general and administrative expenses$4.52B$4.04B$3.81B$3.62B
Other expenses$782M-$-42M-$-88M$11M
Operating expenses$5.31B$4.07B$3.78B$3.69B
Cost and expenses$26.2B$23.3B$21.8B$20.6B
Interest income$0.00$280M$237M$27M
Interest expense$812M$1.31B$1.38B$911M
Depreciation and amortization$704M$977M$951M$933M
Ebitda$1.95B$3.53B$2.59B$1.85B
Operating income$2.21B$2.23B$1.44B$870M
Total other income/expenses, net-$-964M-$-979M-$-1.18B-$-860M
Income before tax$1.25B$1.25B$264M$10M
Income tax expense$91M$46M$30M$35M
Net income$1.16B$1.2B$234M-$-25M
Weighted average shares outstanding$812M$787.1M$787.1M$787.1M
Weighted average diluted shares outstanding$812M$787.1M$787.1M$787.1M
Balance sheet
202520242023
Cash and short-term investments$1.94B$250M$1.59B
Net receivables$3.53B$3.22B$2.96B
Inventory$4.77B$4.46B$3.81B
Total current assets$10.7B$8.27B$8.81B
Property, plant and equipment, net$4.78B$4.98B$4.8B
Goodwill and intangible assets$22B$22.6B$22.3B
Long-term investments$0.00$48M$86M
Total non-current assets$27.8B$27.7B$27.3B
Total assets$38.5B$36B$36.1B
Accounts payable$961M$869M$696M
Short-term debt$77M$154M$122M
Deferred revenue$0.00$0.00$0.00
Total current liabilities$2.49B$2.44B$2.13B
Long-term debt$12.5B$16.7B$16.7B
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$16.7B$17B$17B
Capital lease obligations$0.00$329M$264M
Total liabilities$19.2B$19.5B$19.1B
Common stock$0.00$16.1B$16.6B
Retained earnings-$-7M$0.00$0.00
Accumulated other comprehensive income (loss)$27M$11M$188M
Total equity$19.3B$16.5B$17B
Total investments$0.00$48M$86M
Total debt$12.6B$16.9B$16.8B
Net debt$10.6B$16.6B$15.2B
Cash flow statement
2025202420232022
Net income$1.16B$1.2B$234M-$-25M
Depreciation and amortization$1.01B$977M$951M$933M
Stock-based compensation$0.00$0.00$0.00$0.00
Change in working capital-$-783M-$-675M$199M-$-919M
Accounts receivable-$-355M-$-256M-$-153M-$-376M
Inventory-$-264M-$-545M$444M-$-195M
Accounts payable$73M$106M$136M-$-103M
Net cash provided by operating activities$1.74B$1.77B$1.69B$187M
Investments in property, plant and equipment-$-447M-$-364M-$-285M-$-254M
Acquisitions, net$6M-$-1.13B-$-16M-$-17M
Net cash used for investing activities-$-474M-$-1.49B-$-312M-$-264M
Common stock issued$7.05B$0.00$0.00$0.00
Common stock repurchased-$-2B-$-20M$0.00$0.00
Dividends paid-$-518M$0.00-$-114M$0.00
Net cash used for financing activities$399M-$-1.61B-$-191M-$-84M
Net change in cash$1.69B-$-1.34B$1.59B$0.00
Cash at end of period$1.94B$250M$1.59B$0.00
Operating cash flow$1.74B$1.77B$1.69B$187M
Capital expenditure-$-447M-$-364M-$-285M-$-254M
Free cash flow$1.3B$1.41B$1.4B-$-67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Medline Inc.

        Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings. Offerings range from surgical procedure trays, drapes, and gowns to personal protective equipment (PPE), sterile wraps, various surgical instruments, specialized surgeon's gloves, complete procedure kits, and orthopedic implants. Finally, Laboratory and Diagnostics supplies critical solutions for clinical testing and analysis. This includes point-of-care testing devices, analytical instruments, laboratory consumables, advanced diagnostic equipment, vital signs monitoring systems, and products for anatomic pathology and phlebotomy. The Supply Chain Solutions segment is responsible for sourcing and distributing a diverse portfolio of third-party products, including those from well-known national brands. Beyond distribution, this segment offers comprehensive logistics and supply chain optimization services to clients both domestically and internationally. These optimization services encompass strategic consulting, outsourced management of warehousing and technology, specialized "put-away-ready" packaging, third-party logistics (3PL), inventory rationalization strategies, and efficient route planning. Established in 1966, Medline Inc. maintains its headquarters in Northfield, Illinois.

        CEO
        James Boyle
        Employees
        45K
        Beta
        -0.41

        Explore

        Frequently asked questions

        What is the intrinsic value of Medline Inc. (MDLN)?

        Medline Inc. (MDLN) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MDLN undervalued?

        MDLN trades at a price of $37.04 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.